Leerink Swann Reaffirms “Outperform” Rating for Intellia Therapeutics (NTLA)

Leerink Swann reissued their outperform rating on shares of Intellia Therapeutics (NASDAQ:NTLA) in a report released on Wednesday. Leerink Swann also issued estimates for Intellia Therapeutics’ Q4 2018 earnings at ($0.46) EPS.

Other research analysts have also recently issued reports about the company. Wedbush restated an outperform rating and set a $36.00 price target on shares of Intellia Therapeutics in a research note on Thursday. Barclays upped their price target on Intellia Therapeutics from $33.00 to $46.00 and gave the stock an overweight rating in a research note on Wednesday, March 7th. JMP Securities began coverage on Intellia Therapeutics in a research note on Thursday, March 8th. They set an outperform rating on the stock. TheStreet cut Intellia Therapeutics from a c- rating to a d rating in a research note on Thursday, December 14th. Finally, BidaskClub upgraded Intellia Therapeutics from a buy rating to a strong-buy rating in a research note on Tuesday. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating, six have given a buy rating and one has issued a strong buy rating to the company. Intellia Therapeutics has an average rating of Buy and a consensus price target of $34.83.

Intellia Therapeutics (NASDAQ NTLA) opened at $24.61 on Wednesday. Intellia Therapeutics has a twelve month low of $11.15 and a twelve month high of $35.99. The company has a market capitalization of $1,221.18, a P/E ratio of -13.23 and a beta of 2.42.

Intellia Therapeutics (NASDAQ:NTLA) last released its quarterly earnings data on Wednesday, March 14th. The company reported ($0.61) EPS for the quarter, missing analysts’ consensus estimates of ($0.45) by ($0.16). Intellia Therapeutics had a negative net margin of 258.62% and a negative return on equity of 35.97%. The business had revenue of $6.70 million during the quarter, compared to analyst estimates of $8.84 million. During the same quarter in the prior year, the company posted ($0.31) earnings per share. The company’s revenue was up 19.6% on a year-over-year basis. research analysts expect that Intellia Therapeutics will post -2.25 EPS for the current fiscal year.

In other Intellia Therapeutics news, major shareholder Caribou Biosciences, Inc. sold 550,645 shares of the company’s stock in a transaction on Monday, January 29th. The stock was sold at an average price of $26.78, for a total transaction of $14,746,273.10. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. 12.80% of the stock is owned by corporate insiders.

Several institutional investors have recently bought and sold shares of NTLA. Farallon Capital Management LLC purchased a new stake in shares of Intellia Therapeutics during the fourth quarter worth $21,911,000. ARK Investment Management LLC increased its position in shares of Intellia Therapeutics by 269.2% during the fourth quarter. ARK Investment Management LLC now owns 1,375,149 shares of the company’s stock worth $26,430,000 after acquiring an additional 1,002,671 shares during the period. GMT Capital Corp purchased a new stake in shares of Intellia Therapeutics during the third quarter worth $8,214,000. Shellback Capital LP purchased a new stake in shares of Intellia Therapeutics during the fourth quarter worth $2,343,000. Finally, Capital Advisors Inc. OK purchased a new stake in shares of Intellia Therapeutics during the fourth quarter worth $1,946,000. 68.14% of the stock is currently owned by institutional investors and hedge funds.

TRADEMARK VIOLATION WARNING: This piece was originally published by The Ledger Gazette and is owned by of The Ledger Gazette. If you are viewing this piece on another site, it was illegally copied and republished in violation of US & international copyright law. The legal version of this piece can be read at https://ledgergazette.com/2018/03/17/leerink-swann-reaffirms-outperform-rating-for-intellia-therapeutics-ntla.html.

About Intellia Therapeutics

Intellia Therapeutics, Inc is a genome editing company. The Company is focused on developing therapeutics utilizing a biological tool known as CRISPR/Cas9. The CRISPR/Cas9 genome editing system includes two components: the Cas9 protein and the guide RNA sequence. The Cas9 protein acts like a pair of molecular scissors that initiates the natural cellular repair process to knockout, repair or insert a gene.

Analyst Recommendations for Intellia Therapeutics (NASDAQ:NTLA)

Receive News & Ratings for Intellia Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intellia Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply